GlassScriptPhysician profile
Chad Matthew Lomas
NPI 1265771026
$6,136.62
in general payments reported to CMS, 2019-2025
27 companies · $2,621 in 2025
The $2,621 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.90 · 2021: $334 · 2022: $582 · 2023: $1,028 · 2024: $1,549 · 2025: $2,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,007 · Education: $149 · Consulting Fee: $41.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,006.96 |
| Education | $149.48 |
| Consulting Fee | $41.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,503.59 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $812.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $643.01 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $404.74 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $347.42 | 2021-2025 | Cuvitru, Eohilia, Hyqvia |
| Pharming Healthcare, INC. | $264.36 | 2021-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $244.23 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $243.90 | 2023-2025 | |
| Genentech USA, INC. | $217.98 | 2022-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $191.11 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $152.67 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $149.48 | 2024-2025 | |
| Abbvie INC. | $148.22 | 2024-2025 | |
| Alk-Abello, INC | $118.96 | 2021 | |
| Csl Behring | $112.42 | 2024-2025 | Hizentra, Haegarda |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $100.51 | 2025 | Neffy |
| Amgen INC. | $83.68 | 2023-2025 | Tezspire |
| Kaleo, INC. | $76.57 | 2022-2024 | Auvi-Q |
| Organon LLC | $45.10 | 2025 | Nexplanon |
| Adma Biomanufacturing LLC | $41.95 | 2025 | |
| Optinose US, INC. | $40.94 | 2022-2024 | |
| Blueprint Medicines Corporation | $40.12 | 2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $40.09 | 2022-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.91 | 2022-2023 | Spiriva Respimat |
| Galderma Laboratories, L.P. | $30.29 | 2025 | Nemluvio |
| Lilly USA, LLC | $23.73 | 2025 | Ebglyss |
| Arcutis Biotherapeutics, INC. | $22.39 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Lomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.